AMT-676 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase Ia/Ib study of AMT- 676, followed by an open-label, multicenter, dose-escalation.
| Condition(s) | Advanced Solid Tumors |
|---|---|
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Study type | Interventional |
| Summary | This is a first-in-human, open-label, multicenter Phase Ia/Ib study of AMT- 676, followed by an open-label, multicenter, dose-escalation. |
| Who can participate | Key Inclusion Criteria: 1. Patients must be willing and able to sign the ICF, and to adhere to the study visit Schedule and other protocol requirements. 2. Age ≥18 years (at the time consent is obtained). 3. Patients with pathologically confirmed unresectable advanced solid tumor. Preferred tumor types include colorectal cancer, gastric cancer, esophageal adenocarcinoma, cholangiocarcinoma, pancreatic ductal cancers, and neuroendocrine tumors. 4. Patients who have undergone at least one systemic therapy and have radiologically or clinically determined progressive disease during or after most recent line of therapy, and for whom no further standard therapy is available, or who are intolerable to standard therapy. 5. Patients must have at least one measurable lesion as per RECIST version 1.1 |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Multitude Therapeutics Inc. |
| Locations | Huntersville, North Carolina, American Samoa; Philadelphia, Pennsylvania, American Samoa; San Antonio, Texas, American Samoa; Randwick, New South Wales, Australia; Macquarie, New South wWales, Australia; Greenslopes, Queensland, Australia (+7 more sites) |
| Start date | 2024-06-18 |
| NCT ID | NCT06400485 |
| Official listing | https://clinicaltrials.gov/study/NCT06400485 |